Zobrazeno 1 - 10
of 36
pro vyhledávání: '"E. V. Chernyaeva"'
Autor:
Yu. V. Molochkova, Zh. S. Philippovskaya, А. G. Kupriyanova, E. V. Mitina, O. V. Karzanov, T. E. Sukhova, M. S. Petrova, E. V. Chernyaeva
Publikováno v:
Вестник анестезиологии и реаниматологии, Vol 18, Iss 6, Pp 97-104 (2022)
Toxic epidermal necrolysis (TEN) is a critical life-threating condition developing as the total detachment of epidermidis and characterized by severe pathological reactions of all body systems. The current article describes two cases of TEN with simi
Externí odkaz:
https://doaj.org/article/90c6829e1dca414fa60427740977010e
Autor:
Sh. Erdes, V. I. Mazurov, T. V. Dubinina, I. Z. Gaydukova, S. A. Lapshina, E. V. Zonova, D. G. Krechikova, T. V. Plaksina, O. V. Reshetko, S. A. Smakotina, P. А. Shesternya, I. G. Gordeev, T. G. Makulova, T. V. Povarova, T. A. Raskina, N. F. Soroka, A. M. Pristrom, E. V. Kunder, Yu. V. Usacheva, E. Yu. Stukalina, A. V. Eremeeva, E. V. Chernyaeva, R. A. Ivanov
Publikováno v:
Научно-практическая ревматология, Vol 57, Iss 6, Pp 668-677 (2019)
The paper presents the results of a double-blind (BCD-085-3/AILAS) phase II clinical trial of the original interleukin 17A (IL17A) inhibitor BCD-085 prescribed at different doses to patients with active ankylosing spondylitis (AS) and those of an ext
Externí odkaz:
https://doaj.org/article/d4904fdfb8d74d86b07500bfba5201ae
Autor:
A. L. Bakulev, A. V. Samtsov, A. A. Kubanov, V. R. Khairutdinov, M. M. Kokhan, A. V. Artemyeva, S. I. Derbin, E. V. Chernyaeva, R. A. Ivanov
Publikováno v:
Vestnik Dermatologii i Venerologii, Vol 95, Iss 3, Pp 54-64 (2019)
Netakimabis original monoclonal antibody against IL-17. This article outlines the key results of a phase II open-label extension trial of netakimab 80 mg and 120 mg in patients with moderate-to-severe psoriasis.The main aim of the trial is to estimat
Externí odkaz:
https://doaj.org/article/37963b61b86444bb812f998927a4eb67
Autor:
Т. V. Korotaeva, A. V. Samtsov, A. L. Bakulev, M. M. Kokhan, I. K. Minullin, O. A. Vylegzhanina, V. V. Dubensky, B. V. Khalilov, A. A. Khotko, O. S. Zykova, I. V. Chumachenko, A. M. Lukyanov, A. V. Artemyeva, S. I. Derbin, E. Yu. Stukalina, E. V. Chernyaeva, R. A. Ivanov
Publikováno v:
Современная ревматология, Vol 12, Iss 4, Pp 71-84 (2018)
The paper gives the results of the phase III clinical trial of adalimumab (ADA) biosimilar, (BCD-057) (BIOCAD, Russia), which demonstrate the clinical equivalence of the biosimilar to the ADA innovator Humira® in patients with moderate and severe ps
Externí odkaz:
https://doaj.org/article/dcfec1eedb564d51b6a28f18e8c990d5
Autor:
A. M. Lila, V. I. Mazurov, E. V. Zonova, O. B. Nesmeyanova, T. V. Plaksina, D. G. Krechikova, O. V. Reshet’ko, L. N. Denisov, I. G. Gordeev, T. G. Pokrovskaya, O. V. Antipova, T. V. Kropotina, T. V. Povarova, P. A. Shesternya, E. N. Ushakova, N. F. Soroka, E. V. Kunder, A. V. Eremeeva, E. V. Chernyaeva, R. A. Ivanov, P. S. Pukhtinskaya
Publikováno v:
Научно-практическая ревматология, Vol 56, Iss 3, Pp 293-301 (2018)
The paper gives data on the clinical efficiency and safety profile of long-term use of the infliximab (INF) biosimilar BCD-055 versus the reference drug Remicade® (REM) in a population of patients with active ankylosing spondylitis (AS).Subjects and
Externí odkaz:
https://doaj.org/article/f2ab7d59b1704636a39acc713ecb7947
Autor:
D. E. Karateev, V. I. Mazurov, E. V. Zonova, O. B. Nesmeyanova, T. V. Plaksina, D. G. Krechikova, O. V. Reshetko, L. N. Denisov, I. G. Gordeev, T. G. Pokrovskaya, O. V. Antipova, T. V. Kropotina, T. V. Povarova, P. A. Shesternya, E. N. Ushakova, N. F. Soroka, A. M. Pristrom, A. V. Eremeeva, E. V. Chernyaeva, R. A. Ivanov, U. V. Usacheva
Publikováno v:
Современная ревматология, Vol 11, Iss 3, Pp 14-25 (2017)
This article presents results from two clinical trials of infliximab biosimilar, BCD-055, including comparative data on the pharmacokinetics (PK), efficacy and safety of BCD-055 and innovator infliximab (IFX) in patients with ankylosing spondylitis (
Externí odkaz:
https://doaj.org/article/305ff993592e47ac835d9cdc1c914e7b
Autor:
E. L. Nasonov, V. I. Mazurov, E. V. Zonova, L. A. Knyazeva, I. M. Marusenko, O. B. Nesmeyanova, T. V. Plaksina, Yu. S. Shapovalova, E. P. Ilivanova, D. G. Krechikova, N. A. Petrochenkova, O. V. Reshetko, L. N. Denisov, I. G. Gordeev, A. F. Davydova, N. A. Eremina, E. V. Zemerova, T. B. Ivanova, A. A. Kastanayan, T. G. Pokrovskaya, S. A. Smakotina, E. A. Smolyarchuk, A. V. Artemyeva, R. A. Ivanov, Yu. V. Usacheva, E. V. Chernyaeva
Publikováno v:
Научно-практическая ревматология, Vol 55, Iss 4, Pp 351-359 (2017)
The Russian biotechnological company «BIOCAD» has designed a chimeric monoclonal antibody against CD20 (BCD-020, Acellbia®) that is a biosimilar of rituximab (RTM; MabThera®, F. Hoffmann-La Roche Ltd., Switzerland). In recent years, there has bee
Externí odkaz:
https://doaj.org/article/b1c240855964421db5640cb92522328f
Autor:
E. L. Nasonov, V. I. Mazurov, Yu. V. Usacheva, E. V. Chernyaeva, Ya. Yu. Ustyugov, A. B. Ulitin, R. A. Ivanov
Publikováno v:
Научно-практическая ревматология, Vol 55, Iss 2, Pp 201-210 (2017)
The paper analyzes the key biological effects of cytokines that play a central role in the pathogenesis of immunoinflammatory rheumatic diseases. Special attention is drawn to major proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α)
Externí odkaz:
https://doaj.org/article/59fe075e604e49ccb1590bbacd046b58
Autor:
E. L. Nasonov, E. V. Zonova, O. N. Ivanova, L. A. Knyazeva, V. I. Mazurov, R. R. Samigullina, I. M. Marusenko, O. B. Nesmeyanova, T. V. Plaksina, A. E. Sizikov, D. G. Krechikova, N. A. Petrochenkova, Yu. S. Shapovalova, N. S. Soroka, S. I. Pimanov, A. M. Pristrom, E. V. Kunder, E. V. Chernyaeva, A. V. Eremeeva, R. Ivanov
Publikováno v:
Научно-практическая ревматология, Vol 54, Iss 5, Pp 510-519 (2016)
The article considers the results of an international multicenter randomized clinical trial of the efficacy and safety of the brand-name drug rituximab (MabThera), a monoclonal antibody against CD20 antigen of B cells, and its biosimi-lar drug (Acell
Externí odkaz:
https://doaj.org/article/1851db3d61f34b5b9904808e9377604d
Publikováno v:
Issledovaniâ i Praktika v Medicine, Vol 2, Iss 1, Pp 8-12 (2015)
Objective. Evaluation of pharmacokinetics, pharmacodynamics, safety and efficacy of rituximab biosimilar (Acellbia, BIOCAD, Russia) used as monotherapy in patients with indolent B-cell non-Hodgkin’s lymphoma in comparison with the parameters of inn
Externí odkaz:
https://doaj.org/article/7616405cadf64c2a9ad434b29255cf2b